NCT04430699 2026-03-19Cisplatin+Pembrolizumab+RT in Vulvar CancerMassachusetts General HospitalPhase 2 Active not recruiting24 enrolled
NCT03277482 2025-05-31Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerDana-Farber Cancer InstitutePhase 1 Terminated16 enrolled